8-K filing — FENNEC PHARMACEUTICALS INC. (FENC)
Filed: 2026-09-17 AccNo: 0001104659-26-108565 Size: 220 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.